NASDAQ:NTLA

Intellia Therapeutics Competitors

$51.81

-2.61 (-4.80 %)

(As of 03/5/2021 12:00 AM ET)

Add

Compare

Today's Range

$43.86

Now: $51.81▼

$55.34

50-Day Range

$54.42

MA: $68.87▼

$83.68

52-Week Range

$9.18

Now: $51.81▼

$92.00

Volume3.21 million shs

Average Volume1.77 million shs

Market Capitalization$3.51 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.09

Intellia Therapeutics (NASDAQ:NTLA) Vs. QDEL, NEOG, RIOT, MYGN, HSKA, and LNTH

Should you be buying NTLA stock or one of its competitors? Companies in the industry of "diagnostic substances" are considered alternatives and competitors to Intellia Therapeutics, including Quidel (QDEL), Neogen (NEOG), Riot Blockchain (RIOT), Myriad Genetics (MYGN), Heska (HSKA), and Lantheus (LNTH).

Intellia Therapeutics vs. Quidel Stock

Quidel (NASDAQ:QDEL) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Quidel and Intellia Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quidel	36.91%	63.31%	40.55%
Intellia Therapeutics	-193.01%	-40.14%	-30.11%

Valuation and Earnings

This table compares Quidel and Intellia Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quidel	$534.89 million	11.97	$72.92 million	$2.73	55.42
Intellia Therapeutics	$43.10 million	81.41	$-99,530,000.00	($2.11)	-24.55

Quidel has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Quidel has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Institutional and Insider Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 95.6% of Intellia Therapeutics shares are owned by institutional investors. 14.1% of Quidel shares are owned by insiders. Comparatively, 4.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Quidel and Intellia Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quidel	1	1	3	0	2.40
Intellia Therapeutics	0	5	10	0	2.67

Quidel currently has a consensus price target of $245.60, indicating a potential upside of 62.33%. Intellia Therapeutics has a consensus price target of $56.6154, indicating a potential upside of 9.28%. Given Quidel's higher probable upside, research analysts clearly believe Quidel is more favorable than Intellia Therapeutics.

Summary

Quidel beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.

Intellia Therapeutics vs. Neogen Stock

Neogen (NASDAQ:NEOG) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Neogen and Intellia Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neogen	13.92%	8.13%	7.45%
Intellia Therapeutics	-193.01%	-40.14%	-30.11%

Valuation and Earnings

This table compares Neogen and Intellia Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$418.17 million	10.15	$59.47 million	$1.13	70.58
Intellia Therapeutics	$43.10 million	81.41	$-99,530,000.00	($2.11)	-24.55

Neogen has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Neogen has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Institutional and Insider Ownership

92.8% of Neogen shares are owned by institutional investors. Comparatively, 95.6% of Intellia Therapeutics shares are owned by institutional investors. 0.9% of Neogen shares are owned by insiders. Comparatively, 4.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Neogen and Intellia Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	0	2	1	0	2.33
Intellia Therapeutics	0	5	10	0	2.67

Neogen currently has a consensus price target of $81.50, indicating a potential upside of 2.19%. Intellia Therapeutics has a consensus price target of $56.6154, indicating a potential upside of 9.28%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Neogen.

Intellia Therapeutics vs. Riot Blockchain Stock

Riot Blockchain (NASDAQ:RIOT) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Valuation and Earnings

This table compares Riot Blockchain and Intellia Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Riot Blockchain	$6.84 million	397.87	$-20,040,000.00	($0.73)	-55.21
Intellia Therapeutics	$43.10 million	81.41	$-99,530,000.00	($2.11)	-24.55

Riot Blockchain has higher earnings, but lower revenue than Intellia Therapeutics. Riot Blockchain is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Riot Blockchain has a beta of 4.56, meaning that its share price is 356% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Riot Blockchain and Intellia Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Riot Blockchain	0	0	1	0	3.00
Intellia Therapeutics	0	5	10	0	2.67

Riot Blockchain currently has a consensus price target of $28.00, indicating a potential downside of 30.52%. Intellia Therapeutics has a consensus price target of $56.6154, indicating a potential upside of 9.28%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Riot Blockchain.

Profitability

This table compares Riot Blockchain and Intellia Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Riot Blockchain	-250.06%	-51.38%	-47.50%
Intellia Therapeutics	-193.01%	-40.14%	-30.11%

Institutional and Insider Ownership

9.0% of Riot Blockchain shares are owned by institutional investors. Comparatively, 95.6% of Intellia Therapeutics shares are owned by institutional investors. 3.5% of Riot Blockchain shares are owned by insiders. Comparatively, 4.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Intellia Therapeutics beats Riot Blockchain on 9 of the 14 factors compared between the two stocks.

Intellia Therapeutics vs. Myriad Genetics Stock

Intellia Therapeutics (NASDAQ:NTLA) and Myriad Genetics (NASDAQ:MYGN) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Valuation & Earnings

This table compares Intellia Therapeutics and Myriad Genetics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$43.10 million	81.41	$-99,530,000.00	($2.11)	-24.55
Myriad Genetics	$638.60 million	3.28	$-199,500,000.00	($0.35)	-79.54

Intellia Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Intellia Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Intellia Therapeutics and Myriad Genetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	0	5	10	0	2.67
Myriad Genetics	3	3	0	0	1.50

Intellia Therapeutics presently has a consensus target price of $56.6154, indicating a potential upside of 9.28%. Myriad Genetics has a consensus target price of $17.20, indicating a potential downside of 38.22%. Given Intellia Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Myriad Genetics.

Profitability

This table compares Intellia Therapeutics and Myriad Genetics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-193.01%	-40.14%	-30.11%
Myriad Genetics	-32.49%	-4.07%	-2.68%

Institutional and Insider Ownership

95.6% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Myriad Genetics shares are owned by institutional investors. 4.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 2.8% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Intellia Therapeutics vs. Heska Stock

Intellia Therapeutics (NASDAQ:NTLA) and Heska (NASDAQ:HSKA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Valuation & Earnings

This table compares Intellia Therapeutics and Heska's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$43.10 million	81.41	$-99,530,000.00	($2.11)	-24.55
Heska	$122.66 million	13.26	$-1,470,000.00	$0.05	3,433.60

Heska has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Intellia Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Heska has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Intellia Therapeutics and Heska, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	0	5	10	0	2.67
Heska	0	1	4	0	2.80

Intellia Therapeutics presently has a consensus target price of $56.6154, indicating a potential upside of 9.28%. Heska has a consensus target price of $185.80, indicating a potential upside of 8.22%. Given Intellia Therapeutics' higher possible upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Heska.

Profitability

This table compares Intellia Therapeutics and Heska's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-193.01%	-40.14%	-30.11%
Heska	-11.15%	-2.29%	-1.64%

Institutional and Insider Ownership

95.6% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Heska shares are owned by institutional investors. 4.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 11.7% of Heska shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Heska beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.

Intellia Therapeutics vs. Lantheus Stock

Intellia Therapeutics (NASDAQ:NTLA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Valuation & Earnings

This table compares Intellia Therapeutics and Lantheus' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$43.10 million	81.41	$-99,530,000.00	($2.11)	-24.55
Lantheus	$347.34 million	3.67	$31.67 million	$1.17	16.29

Lantheus has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Intellia Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Intellia Therapeutics and Lantheus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	0	5	10	0	2.67
Lantheus	0	1	3	0	2.75

Intellia Therapeutics presently has a consensus target price of $56.6154, indicating a potential upside of 9.28%. Lantheus has a consensus target price of $23.6667, indicating a potential upside of 24.17%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Intellia Therapeutics.

Profitability

This table compares Intellia Therapeutics and Lantheus' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-193.01%	-40.14%	-30.11%
Lantheus	0.12%	11.05%	5.43%

Institutional and Insider Ownership

95.6% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 85.0% of Lantheus shares are owned by institutional investors. 4.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 2.1% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Lantheus beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.